Chemo Brain Prehab Project
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-85
SponsorDr. Chris Gaffney
About this trial
Colorectal cancer is 37% higher in the North West than the national average and is treated by chemotherapy, including fluorouracil, capecitabine, and oxaliplatin. A side effect of these drugs is loss of memory, forgetfulness, and general brain fog, which can persist for months after the end of treatment. These symptoms are collectively known as 'chemo-brain'. An existing prehabilitation intervention that has been previously developed will be used, which increases fitness and reduces hospital length of stay in colorectal cancer surgery patients, to try to improve the symptoms of chemo-brain in those undergoing chemotherapy and improve quality of life.
Eligibility criteria
Qualifiers
Individuals with stage II or III colorectal cancer undergoing chemotherapy with fluorouracil, capecitabine, or oxaliplatin.
Aged 60-85 years old.
Fluent in English
Male and female participants
Disqualifiers
Presence of comorbidities that may significantly alter the metabolic response to exercise (e.g., diabetes mellitus).
Current musculoskeletal injury or physical limitations that prevent completion of cardiopulmonary exercise testing (CPET).
Any contraindication to the multivitamin supplementation (Forceval), including known hypercalcaemia, haemochromatosis, peanut or soya allergy, current use of phenytoin or tetracycline antibiotics, and clinically significant impaired renal or hepatic function.
Evidence of pre-existing cognitive impairment, including diagnosis of dementia, other neurodegenerative disorders (e.g., Alzheimer's disease), or clinically indicated mild cognitive impairment.
Trial design
Treatments tested in this trial
- Exercise Prehabilitation
- Multivitamins
- Standard Care (in control arm)
Treatment groups
86 Participants
are divided into 2 treatment groupsSponsors and collaborators
Dr. Chris Gaffney
Lead sponsor
Lancaster University
Sponsor institution
Source ClinicalTrials.gov